Short-term effects of pamidronate on bone turnover

Can bone markers be considered predictive of the analgesic response?

A. Martinetti, Carla Ripamonti, R. Miceli, E. Seregni, L. Mariani, F. De Conno, E. Bajetta, E. Bombardieri

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Few data are available on the ability of bone markers to predict the symptomatic response to bisphosphonate therapy in patients with painful bone metastases. We evaluated the levels of bone markers in patients with bone metastases receiving pamidronate and determined the corresponding analgesic response. Forty-two patients were administered two two-week cycles of intravenous pamidronate 60 mg/week with a three-week interval in between. Serum levels of bone formation, resorption and other bone-associated markers (osteoprotegerin, osteopontin and calcium) were measured. Levels of two urinary markers were also measured and the intensity of pain and analgesic drug consumption evaluated. A mixed effects linear modelling approach was adopted to account for possible correlation among marker levels and time on study or analgesic response. We created an indicator variable that classified the patients' analgesic response as 'improved/stationary' or 'worsened' determined by patient reported intensity of pain and analgesic drug consumption. Eighteen patients 'worsened' and 24 were 'improved/stationary'. The results of the mixed effects models for testing the association between marker levels and time on study or analgesic response showed: i) the changes in marker levels over time did not significantly differ between the two groups; ii) the overall test for time on study was not statistically significant for C-terminal telopeptide of type I collagen (ICTP), osteoprotegerin and osteopontin; iii) in contrast, ICTP and osteoprotegerin were significantly associated with analgesic response. Biochemical markers of bone turnover, in particular ICTP and osteoprotegerin seem promising for predicting and objectively assessing the analgesic response to pamidronate treatment.

Original languageEnglish
Pages (from-to)1533-1540
Number of pages8
JournalOncology Reports
Volume17
Issue number6
Publication statusPublished - Jun 2007

Fingerprint

pamidronate
Bone Remodeling
Analgesics
Osteoprotegerin
Bone and Bones
Osteopontin
Neoplasm Metastasis
Pain
Aptitude
Diphosphonates
Bone Resorption
Osteogenesis

Keywords

  • Analgesic drugs
  • Bone metabolism markers
  • Bone metastases
  • Cancer-related pain
  • Pamidronate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Short-term effects of pamidronate on bone turnover : Can bone markers be considered predictive of the analgesic response? / Martinetti, A.; Ripamonti, Carla; Miceli, R.; Seregni, E.; Mariani, L.; De Conno, F.; Bajetta, E.; Bombardieri, E.

In: Oncology Reports, Vol. 17, No. 6, 06.2007, p. 1533-1540.

Research output: Contribution to journalArticle

@article{6a1e25c9351c4d4195de342b5984b850,
title = "Short-term effects of pamidronate on bone turnover: Can bone markers be considered predictive of the analgesic response?",
abstract = "Few data are available on the ability of bone markers to predict the symptomatic response to bisphosphonate therapy in patients with painful bone metastases. We evaluated the levels of bone markers in patients with bone metastases receiving pamidronate and determined the corresponding analgesic response. Forty-two patients were administered two two-week cycles of intravenous pamidronate 60 mg/week with a three-week interval in between. Serum levels of bone formation, resorption and other bone-associated markers (osteoprotegerin, osteopontin and calcium) were measured. Levels of two urinary markers were also measured and the intensity of pain and analgesic drug consumption evaluated. A mixed effects linear modelling approach was adopted to account for possible correlation among marker levels and time on study or analgesic response. We created an indicator variable that classified the patients' analgesic response as 'improved/stationary' or 'worsened' determined by patient reported intensity of pain and analgesic drug consumption. Eighteen patients 'worsened' and 24 were 'improved/stationary'. The results of the mixed effects models for testing the association between marker levels and time on study or analgesic response showed: i) the changes in marker levels over time did not significantly differ between the two groups; ii) the overall test for time on study was not statistically significant for C-terminal telopeptide of type I collagen (ICTP), osteoprotegerin and osteopontin; iii) in contrast, ICTP and osteoprotegerin were significantly associated with analgesic response. Biochemical markers of bone turnover, in particular ICTP and osteoprotegerin seem promising for predicting and objectively assessing the analgesic response to pamidronate treatment.",
keywords = "Analgesic drugs, Bone metabolism markers, Bone metastases, Cancer-related pain, Pamidronate",
author = "A. Martinetti and Carla Ripamonti and R. Miceli and E. Seregni and L. Mariani and {De Conno}, F. and E. Bajetta and E. Bombardieri",
year = "2007",
month = "6",
language = "English",
volume = "17",
pages = "1533--1540",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Short-term effects of pamidronate on bone turnover

T2 - Can bone markers be considered predictive of the analgesic response?

AU - Martinetti, A.

AU - Ripamonti, Carla

AU - Miceli, R.

AU - Seregni, E.

AU - Mariani, L.

AU - De Conno, F.

AU - Bajetta, E.

AU - Bombardieri, E.

PY - 2007/6

Y1 - 2007/6

N2 - Few data are available on the ability of bone markers to predict the symptomatic response to bisphosphonate therapy in patients with painful bone metastases. We evaluated the levels of bone markers in patients with bone metastases receiving pamidronate and determined the corresponding analgesic response. Forty-two patients were administered two two-week cycles of intravenous pamidronate 60 mg/week with a three-week interval in between. Serum levels of bone formation, resorption and other bone-associated markers (osteoprotegerin, osteopontin and calcium) were measured. Levels of two urinary markers were also measured and the intensity of pain and analgesic drug consumption evaluated. A mixed effects linear modelling approach was adopted to account for possible correlation among marker levels and time on study or analgesic response. We created an indicator variable that classified the patients' analgesic response as 'improved/stationary' or 'worsened' determined by patient reported intensity of pain and analgesic drug consumption. Eighteen patients 'worsened' and 24 were 'improved/stationary'. The results of the mixed effects models for testing the association between marker levels and time on study or analgesic response showed: i) the changes in marker levels over time did not significantly differ between the two groups; ii) the overall test for time on study was not statistically significant for C-terminal telopeptide of type I collagen (ICTP), osteoprotegerin and osteopontin; iii) in contrast, ICTP and osteoprotegerin were significantly associated with analgesic response. Biochemical markers of bone turnover, in particular ICTP and osteoprotegerin seem promising for predicting and objectively assessing the analgesic response to pamidronate treatment.

AB - Few data are available on the ability of bone markers to predict the symptomatic response to bisphosphonate therapy in patients with painful bone metastases. We evaluated the levels of bone markers in patients with bone metastases receiving pamidronate and determined the corresponding analgesic response. Forty-two patients were administered two two-week cycles of intravenous pamidronate 60 mg/week with a three-week interval in between. Serum levels of bone formation, resorption and other bone-associated markers (osteoprotegerin, osteopontin and calcium) were measured. Levels of two urinary markers were also measured and the intensity of pain and analgesic drug consumption evaluated. A mixed effects linear modelling approach was adopted to account for possible correlation among marker levels and time on study or analgesic response. We created an indicator variable that classified the patients' analgesic response as 'improved/stationary' or 'worsened' determined by patient reported intensity of pain and analgesic drug consumption. Eighteen patients 'worsened' and 24 were 'improved/stationary'. The results of the mixed effects models for testing the association between marker levels and time on study or analgesic response showed: i) the changes in marker levels over time did not significantly differ between the two groups; ii) the overall test for time on study was not statistically significant for C-terminal telopeptide of type I collagen (ICTP), osteoprotegerin and osteopontin; iii) in contrast, ICTP and osteoprotegerin were significantly associated with analgesic response. Biochemical markers of bone turnover, in particular ICTP and osteoprotegerin seem promising for predicting and objectively assessing the analgesic response to pamidronate treatment.

KW - Analgesic drugs

KW - Bone metabolism markers

KW - Bone metastases

KW - Cancer-related pain

KW - Pamidronate

UR - http://www.scopus.com/inward/record.url?scp=34548016567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548016567&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 1533

EP - 1540

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -